Bristol-Myers Squibb Company ((BMY)), ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bristol-Myers Squibb Company, in collaboration with ONO Pharmaceutical Co., is conducting an observational study titled ‘An Observational Study Evaluating Treatment Situations of Adjuvant Nivolumab for Muscle-invasive Urothelial Carcinoma in Japan.’ The study aims to assess the effectiveness and safety of nivolumab, an adjuvant treatment for muscle-invasive urothelial carcinoma (MIUC), including bladder, renal pelvis, and ureteral cancer, in a real-world Japanese clinical setting.
The intervention being tested is nivolumab, an immunotherapy drug designed to enhance the body’s immune response against cancer cells. It is used as an adjuvant treatment to improve outcomes for patients with MIUC.
This observational study follows a cohort model, focusing on patients who have received nivolumab as an adjuvant treatment. The primary purpose is to gather real-world data on treatment effectiveness and safety, without any specific allocation or masking involved.
The study began on November 23, 2022, with a primary completion date set for December 31, 2023. The last update was submitted on June 26, 2025, indicating ongoing data collection and analysis.
The update on this study could influence Bristol-Myers Squibb’s and ONO Pharmaceutical’s stock performance by potentially increasing investor confidence in nivolumab’s market potential. As the pharmaceutical industry is highly competitive, positive results could strengthen these companies’ positions in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.